ALPHAREDISOL Drug Patent Profile
✉ Email this page to a colleague
When do Alpharedisol patents expire, and when can generic versions of Alpharedisol launch?
Alpharedisol is a drug marketed by Merck and is included in one NDA.
The generic ingredient in ALPHAREDISOL is hydroxocobalamin. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alpharedisol
A generic version of ALPHAREDISOL was approved as hydroxocobalamin by ACTAVIS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALPHAREDISOL?
- What are the global sales for ALPHAREDISOL?
- What is Average Wholesale Price for ALPHAREDISOL?
Summary for ALPHAREDISOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| DailyMed Link: | ALPHAREDISOL at DailyMed |
US Patents and Regulatory Information for ALPHAREDISOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ALPHAREDISOL | hydroxocobalamin | INJECTABLE;INJECTION | 080778-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ALPHAREDISOL
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| SERB SA | Cyanokit | hydroxocobalamin | EMEA/H/C/000806 Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures. |
Authorised | no | no | no | 2007-11-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
